Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Jane de Vries

Impact of Peanut Allergy on Quality of Life: Baseline Results From PALISADE, a Phase 3, Double-Blind, Placebo-Controlled Trial for AR101 Oral Immunotherapy

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Treatment Satisfaction in Systemic Lupus Erythematosus

Journal of Clinical Rheumatology
MedicineRheumatology
2017English

Related publications

Efficacy and Safety of AR101 in Peanut Allergy: Results From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (PALISADE)

Journal of Allergy and Clinical Immunology
AllergyImmunology
2018English

Prevalence of Comorbidities With Peanut Allergy: Results From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (PALISADE)

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial

Pediatrics
Child HealthPediatricsPerinatology
2018English

Estimating the Probability of Tolerating Each Challenge Dose of Peanut Protein at Exit Double-Blind, Placebo-Controlled Food Challenge: Results From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (PALISADE) of AR101

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Accidental Exposures to Peanut and Other Food Allergens: Results From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (PALISADE)

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

AR101 Oral Immunotherapy for Peanut Allergy

Pediatrics
Child HealthPediatricsPerinatology
2019English

Longer-Term Safety and Efficacy Measures of AR101 Oral Immunotherapy for Peanut Allergy: Results From a Phase 3 Follow-On Study

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Pnd152 - Impact of Inotersen on Generic Health-Related Quality of Life for Patients With Hattr Amyloidosis: Results From a Double-Blind Placebo-Controlled Trial

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pnd150 - Impact of Inotersen on Condition-Specific Quality of Life (Qol) for Patients With Hattr Amyloidosis: Results From a Double-Blind Placebo-Controlled Trial

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy